​

Elevance Health (ELV) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ELV Stock Forecast

Elevance Health (ELV) stock forecast, based on 34 Wall Street analysts, predicts a 12-month average price target of $505.40, with a high of $529.00 and a low of $478.00. This represents a 16.17% increase from the last price of $435.04.

$350 $400 $450 $500 $550 $600 High: $529 Avg: $505.4 Low: $478 Last Closed Price: $435.04

ELV Stock Rating

Elevance Health stock's rating consensus is Buy, based on 34 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 26 Buy (76.47%), 8 Hold (23.53%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 34 0 8 26 Strong Sell Sell Hold Buy Strong Buy

ELV Price Target Upside V Benchmarks

TypeNameUpside
StockElevance Health16.17%
SectorHealthcare Stocks 33.91%
IndustryHealthcare Plans Stocks9.88%

Price Target Trends

1M3M12M
# Anlaysts--15
Avg Price Target--$576.93
Last Closing Price$435.04$435.04$435.04
Upside/Downside--32.62%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 255134--22
Mar, 255125--22
Feb, 255125--22
Jan, 255145--24
Dec, 246144--24
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 21, 2024David WindleyJefferies$529.00$430.7722.80%21.60%
Oct 21, 2024Whit MayoLeerink Partners$515.00$430.7719.55%18.38%
Oct 18, 2024Sarah JamesRaymond James$485.00$432.5312.13%11.48%
Oct 18, 2024Ben HendrixRBC Capital$478.00$444.357.57%9.87%
Oct 18, 2024David MacDonaldTruist Financial$520.00$444.3517.02%19.53%
Oct 16, 2024Michael HaRobert W. Baird$625.00$483.8729.17%43.66%
Jul 18, 2024Ben HendrixRBC Capital$585.00$502.0616.52%34.47%
Jul 15, 2024David MacDonaldTruist Financial$620.00$535.5415.77%42.52%
Jun 24, 2024Erin WrightMorgan Stanley$643.00$534.4220.32%47.80%
May 29, 2024Michael HaRobert W. Baird$649.00$505.5228.38%49.18%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 28, 2025BernsteinOutperformOutperformhold
Oct 21, 2024Cowen & Co.BuyBuyhold
Oct 21, 2024JefferiesBuyBuyhold
Oct 21, 2024Leerink PartnersOutperformOutperformhold
Oct 18, 2024UBSBuyBuyhold
Oct 18, 2024Wells FargoBuyBuyhold
Oct 18, 2024RBC CapitalOutperformOutperformhold
Oct 10, 2024BarclaysOverweightOverweighthold
Aug 19, 2024Wells FargoBuyBuyhold
Jul 19, 2024Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$15 $25 $35 $45 $55 $65 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$18.23$25.04$24.56$25.69$25.68-----
Avg Forecast$22.42$25.94$29.02$33.07$33.21$34.49$39.12$45.09$53.01$60.81
High Forecast$23.15$26.78$29.93$33.17$33.39$35.31$43.70$46.79$55.16$63.27
Low Forecast$21.54$24.92$27.99$33.01$32.43$31.08$34.75$42.00$50.33$57.73
Surprise %-18.69%-3.47%-15.37%-22.32%-22.67%-----

Revenue Forecast

$100B $140B $180B $220B $260B $300B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$121.87B$138.64B$156.59B$171.34B$176.81B-----
Avg Forecast$120.37B$137.85B$156.30B$170.38B$175.83B$191.75B$205.47B$221.23B$241.40B$279.48B
High Forecast$123.37B$141.29B$160.07B$171.02B$177.24B$196.06B$217.15B$222.36B$248.91B$288.17B
Low Forecast$116.70B$133.66B$152.01B$169.32B$174.23B$183.87B$194.40B$220.09B$232.01B$268.60B
Surprise %1.25%0.57%0.19%0.56%0.56%-----

Net Income Forecast

$0 $3B $6B $9B $12B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$4.57B$6.10B$5.89B$5.99B$5.98B-----
Avg Forecast$4.48B$5.67B$6.08B$5.99B$7.67B$7.74B$9.14B$10.35B$12.36B$14.17B
High Forecast$5.38B$6.81B$7.30B$7.18B$7.78B$8.23B$10.19B$10.91B$12.86B$14.75B
Low Forecast$3.59B$4.54B$4.87B$4.79B$7.56B$7.24B$8.10B$9.79B$11.73B$13.46B
Surprise %1.99%7.56%-3.08%--22.05%-----

ELV Forecast FAQ

Is Elevance Health stock a buy?

Elevance Health stock has a consensus rating of Buy, based on 34 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 26 Buy, 8 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Elevance Health is a favorable investment for most analysts.

What is Elevance Health's price target?

Elevance Health's price target, set by 34 Wall Street analysts, averages $505.4 over the next 12 months. The price target range spans from $478 at the low end to $529 at the high end, suggesting a potential 16.17% change from the previous closing price of $435.04.

How does Elevance Health stock forecast compare to its benchmarks?

Elevance Health's stock forecast shows a 16.17% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the healthcare plans stocks industry (9.88%).

What is the breakdown of analyst ratings for Elevance Health over the past three months?

  • April 2025: 22.73% Strong Buy, 59.09% Buy, 18.18% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 22.73% Strong Buy, 54.55% Buy, 22.73% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 22.73% Strong Buy, 54.55% Buy, 22.73% Hold, 0% Sell, 0% Strong Sell.

What is Elevance Health’s EPS forecast?

Elevance Health's average annual EPS forecast for its fiscal year ending in December 2025 is $34.49, marking a 34.31% increase from the reported $25.68 in 2024. Estimates for the following years are $39.12 in 2026, $45.09 in 2027, $53.01 in 2028, and $60.81 in 2029.

What is Elevance Health’s revenue forecast?

Elevance Health's average annual revenue forecast for its fiscal year ending in December 2025 is $191.75B, reflecting a 8.45% increase from the reported $176.81B in 2024. The forecast for 2026 is $205.47B, followed by $221.23B for 2027, $241.4B for 2028, and $279.48B for 2029.

What is Elevance Health’s net income forecast?

Elevance Health's net income forecast for the fiscal year ending in December 2025 stands at $7.74B, representing an 29.38% increase from the reported $5.98B in 2024. Projections indicate $9.14B in 2026, $10.35B in 2027, $12.36B in 2028, and $14.17B in 2029.